Browse News
Filter News
Found 2,803 articles
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
4/18/2024
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades.
-
Gene Therapy Market Size Poised to Surge USD 52.40 Billion by 2033
4/18/2024
The global gene therapy market size was valued at USD 8.75 billion in 2023 and is poised to grow from USD 10.47 billion in 2024
-
Inflammatory disease–focused Mirador Therapeutics landed the largest early-stage VC investment in biopharma last quarter, as more companies are securing $150 million or more.
-
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
4/17/2024
Stoke Therapeutics, Inc. today announced the appointment of Jason Hoitt as Chief Commercial Officer.
-
Endeavor BioMedicines Announces Appointment of Chris Krueger, J.D., as Chief Operating Officer
4/16/2024
Endeavor BioMedicines today announced the appointment of Chris Krueger, J.D., as Chief Operating Officer (COO). Mr. Krueger brings extensive experience from the life sciences industry that will be instrumental to Endeavor's continued growth and success.
-
Obsidian Therapeutics Appoints Jeffrey Trigilio as Chief Financial Officer
4/15/2024
Obsidian Therapeutics, Inc. today announced the appointment of Jeffrey Trigilio as Chief Financial Officer, effective May 1, 2024.
-
Vertex Pharmaceuticals on Wednesday announced it is acquiring clinical-stage immunotherapy company Alpine Immune Sciences for $4.9 billion in cash, the largest acquisition so far this year.
-
Follow along as BioSpace keeps you up to date on the latest pharma and biotech M&As, from announcements to closings.
-
TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline
4/10/2024
TORL BioTherapeutics, LLC, is a clinical-stage biotechnology company involved in discovery and development of new antibody-based immunotherapies designed to improve and extend the lives of patients with cancer worldwide.
-
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
4/10/2024
Vertex Pharmaceuticals Incorporated and Alpine Immune Sciences, Inc., a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash.
-
Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy
4/10/2024
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) today shared updated clinical data for povetacicept in IgA nephropathy (IgAN) which will be presented as a late breaking poster at the World Congress of Nephrology (WCN) April 13-16, 2024 in Buenos Aires, Argentina.
-
Bayer and Google Cloud to Accelerate Development of AI-powered Healthcare Applications for Radiologists
4/9/2024
Bayer and Google Cloud announced a collaboration on the development of artificial intelligence solutions to support radiologists and ultimately better serve patients.
-
Obsidian Therapeutics Presents Positive 25-Week Median Study Follow-Up Safety and Efficacy Data from First-in-Human Study of OBX-115 in Advanced Melanoma at the American Association for Cancer Research Annual Meeting
4/9/2024
Obsidian Therapeutics, Inc. today provided an update on its Phase 1 first-in-human study of OBX-115 tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced or metastatic melanoma, including 25-week median study follow-up safety data and newly detailed efficacy data, during a presentation at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.
-
Vertex to Announce First Quarter 2024 Financial Results on May 6
4/9/2024
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2024 financial results on Monday, May 6, 2024 after the financial markets close.
-
U.S. Cell Therapy Market Size to Hit USD 19.67 Billion By 2033
4/8/2024
The global U.S. cell therapy market size was valued at USD 2.88 billion in 2023 and is poised to grow from USD 3.49 billion in 2024 to USD 19.67 billion by 2033, growing at a CAGR of 21.18% in the forecast period (2024-2033).
-
Ribometrix Presents First c-MYC Data Validating RNA-Targeting Platform and Demonstrates Synergistic Potential of eIF4E Program at AACR 2024
4/7/2024
Ribometrix, a biotechnology company developing small molecule therapeutics that modulate RNA biology, shared the full data from two posters highlighting advancements across two distinct modalities presented at the 2024 American Association for Cancer Research Annual Meeting, held April 5-10 in San Diego, CA.
-
Nucleai Unveils Breakthrough AI Spatial Biomarker Advancements at AACR 2024 with the Potential to Transform Cancer Diagnostics and Treatments
4/5/2024
Nucleai, a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, will showcase its developments in cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California from April 5-10, 2024.
-
Merck’s Corporate Venture M Ventures Arm Backs Nucleai to Advance Its First-in-class Spatial AI Biomarker in Active Clinical Enrollment
4/3/2024
Nucleai, a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, has secured a $14 million investment led by M Ventures, the corporate venture capital arm of Merck KGaA, Darmstadt, Germany, and supported by existing investors, bringing the total funding to $60 million.
-
Obsidian Therapeutics Announces Oversubscribed $160.5 Million Series C Financing to Drive OBX-115 Clinical Development
4/3/2024
Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a significantly oversubscribed $160.5 million Series C financing with a top-tier syndicate of life science investors led by new investor, Wellington Management.